- Conditions
- Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
- Interventions
- rHSC-DIPGVax, Balstilimab, Zalifrelimab
- Biological · Drug
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- 12 Months to 18 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- Orange, California • Chicago, Illinois • Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–94
of 94
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV-1 Infection
- Interventions
- B/F/TAF (Adult Strength), B/F/TAF (Low Dose), B/F/TAF (TOS)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 10
- States / cities
- Washington D.C., District of Columbia • Ft. Pierce, Florida • Gainesville, Florida + 7 more
- Conditions
- Prostate Cancer
- Interventions
- EPI-7386 (QD), EPI-7386 (BID), Abiraterone acetate, Apalutamide
- Drug
- Lead sponsor
- ESSA Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 7
- States / cities
- Port Saint Lucie, Florida • Atlanta, Georgia • Boston, Massachusetts + 4 more
- Conditions
- Olmsted Syndrome
- Interventions
- KM-023, Placebo
- Drug
- Lead sponsor
- Orvida Pharma (formerly Kamari Pharma)
- Network
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Cystic Fibrosis
- Interventions
- IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 1 Month to 24 Months
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 10 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride, Placebo
- Drug · Other
- Lead sponsor
- Shire
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 396 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 20
- States / cities
- Dothan, Alabama • Anaheim, California • Imperial, California + 17 more
- Conditions
- Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
- Interventions
- Placebo, Baricitinib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 18
- States / cities
- Bakersfield, California • Santa Monica, California • Miami, Florida + 15 more
- Conditions
- Alopecia Areata
- Interventions
- CTP-543, Placebo
- Drug
- Lead sponsor
- Concert Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 317 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 35 more
- Conditions
- Myeloma
- Interventions
- Panobinostat, Bortezomib, Lenalidomide, Dexamethasone, Symptom Questionnaire
- Drug · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Adult Glioblastoma
- Interventions
- Laboratory Biomarker Analysis, Pembrolizumab, Radiation Therapy, Temozolomide
- Other · Biological · Radiation + 1 more
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Giant Cell Arteritis
- Interventions
- Sirukumab, Placebo to match sirukumab, Prednisone, Placebo to match prednisone
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 13
- States / cities
- Aurora, Colorado • Boca Raton, Florida • Naples, Florida + 9 more
- Conditions
- B-cell Malignancies, Cancer
- Interventions
- MEDI-551, Rituximab
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2019
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • La Jolla, California • Washington D.C., District of Columbia + 10 more
- Conditions
- Hereditary Angioedema
- Interventions
- C1 esterase inhibitor [human] (C1INH-nf), Placebo (saline)
- Biological · Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • San Diego, California • Walnut Creek, California + 13 more
- Conditions
- SCN2A Encephalopathy, SCN8A Encephalopathy
- Interventions
- PRAX-562
- Drug
- Lead sponsor
- Praxis Precision Medicines
- Industry
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Minneapolis, Minnesota + 1 more
- Conditions
- Lymphoma
- Interventions
- milatuzumab, veltuzumab, Correlative/Special Studies, Quantitative T-, B-, and NK cell subsets, Pharmacokinetics, Human Anti-Human Antibodies, veltuzumab and milatuzumab
- Biological · Procedure
- Lead sponsor
- Beth Christian
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- PLN-74809, Placebo
- Drug
- Lead sponsor
- Pliant Therapeutics, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 7 more
- Conditions
- Autosomal Dominant Polycystic Kidney Disease, ADPKD, Polycystic Kidney, Autosomal Dominant
- Interventions
- RGLS8429, Placebo
- Drug
- Lead sponsor
- Regulus Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 21
- States / cities
- Mesa, Arizona • Los Angeles, California • New Haven, Connecticut + 17 more
- Conditions
- IgG4 Related Disease, IgG4-RD
- Interventions
- elotuzumab, placebo for elotuzumab, methylprednisolone, diphenhydramine, acetaminophen, famotidine, prednisone
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Rochester, Minnesota
- Conditions
- Rheumatoid Arthritis
- Interventions
- Tirabrutinib, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 9
- States / cities
- Sacramento, California • Miami, Florida • Orlando, Florida + 6 more
- Conditions
- Arthritis, Rheumatoid
- Interventions
- CNTO 136 100 mg, CNTO 136 50 mg, CNTO 136 25 mg, Placebo, Methotrexate
- Drug
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 8
- States / cities
- Aventura, Florida • Lexington, Kentucky • Frederick, Maryland + 5 more
- Conditions
- Glioblastoma Multiforme, Gliosarcoma
- Interventions
- ZD6474, temozolomide, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Patrick Y. Wen, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • Detroit, Michigan • New York, New York + 2 more
- Conditions
- Systemic Lupus Erythematosus, Active Cutaneous Lupus Erythematosus
- Interventions
- BIIB059 (litifilimab), Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 53
- States / cities
- Anniston, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 44 more